Login / Signup

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

James M ClearyNora K HorickNadine Jackson McClearyThomas A AbramsMatthew B YurgelunChristopher G AzzoliDouglas A RubinsonGabriel A BrooksJennifer A ChanLawrence S BlaszkowskyJeffrey W ClarkLipika GoyalJeffrey A MeyerhardtKimmie NgDeborah SchragDiane M F SavareseChristopher GrahamBridget FitzpatrickKathryn A GibbYves BoucherDan G DudaRakesh K JainCharles S FuchsPeter C Enzinger
Published in: Cancer (2019)
Ziv-aflibercept did not increase the anti-tumor activity of first-line mFOLFOX6 in metastatic esophagogastric cancer, potentially because of decreased dose intensity of FOLFOX. Further evaluation of ziv-aflibercept in unselected, chemotherapy-naive patients with metastatic esophagogastric adenocarcinoma is not warranted.
Keyphrases